Oncotarget

Research Papers:

Loss of TXNIP enhances peritoneal metastasis and can be abrogated by dual TORC1/2 inhibition

Douglas Spaeth-Cook, Mark Burch, Robin Belton, Bryce Demoret, Nicholas Grosenbacher, Jason David, Colin Stets, David Cohen, Reena Shakya, John L. Hays and James L. Chen _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2018; 9:35676-35686. https://doi.org/10.18632/oncotarget.26281

Metrics: PDF 743 views  |   HTML 1211 views  |   ?  


Abstract

Douglas Spaeth-Cook1, Mark Burch2, Robin Belton1, Bryce Demoret1, Nicholas Grosenbacher1, Jason David2, Colin Stets1, David Cohen4, Reena Shakya5, John L. Hays3,6,* and James L. Chen1,3,*

1Department of Biomedical Informatics, Division of Bioinformatics, The Ohio State University, Columbus, OH 43210, USA

2Department of Biostatistics, The Ohio State University, Columbus, OH 43210, USA

3Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH 43210, USA

4Department of Pathology, Anatomic Pathology Division, The Ohio State University, Columbus, OH 43210, USA

5James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA

6Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University, Columbus, 43210 OH, USA

*These authors contributed equally to this work

Correspondence to:

James L. Chen, email: James.Chen@osumc.edu

Keywords: carcinomatosis; sarcomatosis; TXNIP; peritoneal disease

Received: July 05, 2018     Accepted: October 06, 2018     Published: November 02, 2018

ABSTRACT

Peritoneal metastasis (PM) is a debilitating consequence of multiple cancers. As cancer cells lose tonic signaling related to attachment dependence, critical morphologic shifts result in alteration of the transcriptome. Identifying key genes associated with this transformation may lead to targeted therapies for this devastating complication. TC71, CHLA9, PANC1, YOU and HEYA8 cell lines were grown as tumor spheroids in polyHEMA coated plates. Temporal profiling of transcriptomic alterations over 72 hrs was used to develop a comprehensive PM model. We identified transcriptomic outliers using Gaussian mixtures model clustering to identify drivers of spheroid formation. Outliers were validated in The Cancer Genome Atlas (TCGA) and an ovarian tissue microarray (TMA) and by modulation in ovarian cancer models in vitro and in peritoneal xenograft models. Outlier analysis of PM genes identified the gene TXNIP and the TORC signaling as central to PM. Ovarian cancer spheroids isolated from patient ascites had significantly higher TXNIP than their attached counterparts (p = 0.047). TXNIP levels predicted progression-free (log-rank p = 0.026) survival in stage 1/2 ovarian cancer and overall survival (log rank p = 0.047) in stage 3/4 ovarian cancer. In vitro, TXNIP silencing was associated with increased mTOR signaling and enhanced spheroid development which could be overcome by TAK228, a TORC1/2 inhibitor. Similarly, in vivo peritoneal xenograft models of carcinomatosis were prevented by TAK228. PM is driven by TXNIP-associated TORC1/2 signaling. This work provides the first evidence that TORC1/2 inhibition may prevent PM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26281